Operating profit before deduction of amortization: Dianthus Therapeutics, Inc. (DNTH)
The stability of Dianthus Therapeutics (DNTH) relies on the expansion of DNTH-103 complement inhibitors within the rare disease segment. This chart of EBITDA_Co confirms this trajectory, where the 0.00 metric determines this level. However, the business is constrained by strict patent barriers and high development costs, while the absence of current sales leads to a gradual depletion of the company's cash reserves.
Dianthus Therapeutics, Inc. (DNTH) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Equity Ratio Dianthus Therapeutics|DNTH - Long-Term Debt to Capital|Current Liabilities to Capital Dianthus Therapeutics Inc|DNTH - Company Aggregate Debts|Debt to Book Value Ratio Dianthus Therapeutics|DNTH - Company Long-Term Debts|Short-Term Debt Volume Dianthus Therapeutics|Quick Ratio dianthustx.com
- earnings and multiples data:
DNTH - Company Net Income|Net Profit Forecast Dianthus Therapeutics|DNTH - Price to Earnings Ratio|Market Cap to Future Earnings Ratio dianthustx.com|DNTH - PEG Multiple|Business Value to Operating Income Before Depreciation Dianthus Therapeutics|DNTH - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Dianthus Therapeutics|DNTH - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months dianthustx.com|DNTH - Net earnings per share growth this year|Expected earnings per share trend next year Dianthus Therapeutics
Summary company analytics:Dianthus Corp - DNTH
The development of self-administration antibodies at Dianthus Therapeutics (DNTH) is directly reflected in the EBITDA chart. This metric captures the actual cash flow from core operations, excluding the impact of taxes and asset depreciation. Investors can see the net result of cash generation, stripped of accounting write-downs. Inelastic demand for complement inhibitors provides the company with significant pricing power, transforming product uniqueness into stable operational efficiency for the business.
Who Dianthus Therapeutics competes with
Operating income before deduction of amortization argenx BVBA (ARGX)|BNTX - Profit before payment of interest, taxes and amortization|Abivax S.A. (ABVX) - Operating profit before deduction of amortization|ADMA Biologics, Inc. (ADMA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Protagonist Therapeutics, Inc.|Operating profit before deduction of amortization IMVT|Operating profit EBITDA Kiniksa Corp|Profit before payment of interest, taxes and amortization Grifols, S.A. (GRFS)|adaptivebiotech.com - Operating profit before amortization|Operating profit EBITDA CLDX (Celldex Therapeutics, Inc.)|Aurinia Pharmaceuticals Inc (AUPH) - Profit before interest, taxes and amortization|BioCryst Pharmaceuticals Inc - Operating profit EBITDA|VERA (Vera Corp) - Operating profit before amortization|PHVS: Operating profit EBITDA|ABCL - Operating income before deduction of amortization|TRML (Tourmaline Bio) - Operating profit EBITDA|Operating profit EBITDA Precigen Inc|Profit before payment of interest, taxes and amortization Pharming (PHAR)|Nektar Corp - Operating profit before amortization|Upstream Bio Inc - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization ZBIO (zenasbio.com)|Immunome - Operating profit EBITDA|Income before deduction of interest, taxes and amortization GOSS (Gossamer Bio Inc)|KALV (KalVista Pharmaceuticals Inc) - Operating profit before deduction of amortization|Septerna Pharma (SEPN) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Pieris Pharmaceuticals|savarapharma.com (SVRA) - Operating income before deduction of amortization|Operating profit before deduction of amortization RIGL (Rigel Pharmaceuticals, Inc.)|ANAB (AnaptysBio Inc) - Income before deduction of interest, taxes and amortization|Astria Pharma - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization ENGN (enGene Corp)|RAPT Therapeutics - Operating profit EBITDA|Income before deduction of interest, taxes and amortization JBIO (Aerovate Therapeutics Inc)|ACRS: Operating profit EBITDA|Profit before interest, taxes and amortization Kyverna Therapeutics Inc. (KYTX)|Profit before payment of interest, taxes and amortization Tiziana Life Sciences PLC|CABA: Income before deduction of interest, taxes and amortization|Operating profit EBITDA VTYX|Operating profit EBITDA theratech.com (THTX)|Profit before payment of interest, taxes and amortization Avalo Therapeutics AVTX|ELDN (Eledon Pharmaceuticals Inc.) - Profit before deduction of interest, taxes, depreciation and amortization|Agenus Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Climb Bio, Inc|ZURA (Zura Bio) - Operating profit before deduction of amortization|atyrpharma.com (ATYR) - Operating profit EBITDA|Operating profit before deduction of amortization ADAG|IMA (Ikena Oncology, Inc.) - Company profit before taxes, interest and amortization|Operating profit EBITDA STTK|Operating income before deduction of amortization equilliumbio.com|Operating profit EBITDA CNTB (Connect Biopharma Holdings Limited)|IMUX - Operating profit before deduction of amortization|ATRA - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization InflaRx N.V. IFRX|XFOR: Operating profit EBITDA|Operating profit before amortization ACET|Profit before payment of interest, taxes and amortization Celularity Inc|Operating profit before amortization INMB (inmunebio.com)|Operating profit before deduction of amortization BRNS (Barinthus Biotherapeutics plc)|Company profit before taxes, interest and amortization KZR|Operating profit EBITDA SABS (SAB Biotherapeutics, Inc)|Income before deduction of interest, taxes and amortization AKTX|ENLV - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization QTTB|GOVX: Operating profit EBITDA|Edesa Biotech Inc - Income before deduction of interest, taxes and amortization|IBIO (iBio Corp) - Operating profit EBITDA|Operating profit EBITDA Carisma Tx|Profit before payment of interest, taxes and amortization XTL Biopharmaceuticals (XTLB)|BOLT (boltbio.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization HCW Biologics HCWB|APVO - Operating profit before deduction of amortization|AIM ImmunoTech Inc. - Operating profit EBITDA|ADTX - Operating profit EBITDA|GRI (GRI Bio, Inc.) - Operating profit before deduction of amortization|xortx.com - Income before deduction of interest, taxes and amortization|HIND (Vyome Holdings) - Operating profit EBITDA|Revelation Biosciences Inc (REVB) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Indaptus (INDP)|Operating profit before deduction of amortization BiondVax Pharmaceuticals SCNI|Profit before payment of interest, taxes and amortization CalciMedica CALI|AFMD - Operating profit before deduction of amortization|ALLK: Operating profit before deduction of amortization|HOOK - Operating profit EBITDA|igmbio.com (IGMS) - Profit before payment of interest, taxes and amortization|Operating profit before amortization ITOS|OCEA (Ocean Biomedical, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization tcbiopharm.com TCBP|Operating profit EBITDA THRD
